Reasons patients give to use or not to use immunomodulating agents for multiple sclerosis

European Journal of Neurology

Volumn 18, Issue 11, 2011, Pages 1343-1349

  Visser, L H ^a   Van Der Zande, A ^b  

^a Microvida Laboratory for Medical Microbiology and Immunology   (Netherlands)

^b Dutch National Multiple Sclerosis Foundation   (Netherlands)

Author keywords

Ceasing or changing treatment; Immunomodulating therapy; Multiple sclerosis

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; GLATIRAMER; IMMUNOGLOBULIN; INTERFERON BETA SERINE; MITOXANTRONE;

ADULT; ARTICLE; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DRUG ACTIVITY; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG USE; DRUG WITHDRAWAL; FEMALE; FLU LIKE SYNDROME; HEALTH SURVEY; HUMAN; INJECTION SITE HYPERSENSITIVITY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RELAPSE;

ADULT; FEMALE; HEALTH SURVEYS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOMODULATION; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NETHERLANDS; PATIENT PREFERENCE; PHYSICIAN-PATIENT RELATIONS;

EID: 80053918905     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2011.03411.x     Document Type: Article

References (11)

1. Goodin DS, Frohman EM, Garmany GP Jr, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002; 58: 169-178.
2. Anonymous. League table puts pressure on nations to improve MS care. Lancet Neurol 2008; 7: 467.
3. Tremlett HL, Oger J. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. Neurology 2003; 61: 551-554.
4. Tremlett H, Van der Mei I, Pittas F, et al. Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses. Pharmacoepidemiol Drug Saf 2008; 17: 565-576.
5. Milanese C, La Mantia L, Palumbo R, et al. A post-marketing study on interferon beta 1b and 1a treatment in relapsing-remitting multiple sclerosis: different response in drop-outs and treated patients. J Neurol Neurosurg Psychiatry 2003; 74: 1689-1692.
6. O'Rourke KE, Hutchinson M. Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns. Mult Scler 2005; 11: 46-50.
7. Limmroth V, Malessa R, Zettl UK, et al. Quality Assessment in Multiple Sclerosis Therapy (QUASIMS): a comparison of interferon beta therapies for relapsing-remitting multiple sclerosis. J Neurol 2007; 254: 67-77.
8. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000; 343: 938-952.
9. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000; 343: 1430-1438.
10. Mohr DC, Goodkin DE, Likosky W, et al. Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-1b: relationship to adherence to treatment. Mult Scler 1996; 2: 222-226.
11. Rio J, Porcel J, Tellez N, et al. Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult Scler 2005; 11: 306-309.